drugset / Trial / NCT04565379
Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in COVID-19 pneumonia patients
Timeline
- Start
- 2020-09-24
- Primary completion
- 2021-04-13
- Completion
- 2021-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NuSepin® | Unknown | 0.1 mg/kg | Intravenous |
| Comparator | NuSepin® | Unknown | 0.2 mg/kg | Intravenous |